Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2a Feasibility Study of T3D-959 in Subjects With Mild to Moderate Alzheimer's Disease

NCT02560753 is registered in ClinicalTrials.gov with T3D Therapeutics, Inc. as lead sponsor.

NCT NCT02560753
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02560753 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2a Feasibility Study of T3D-959 in Subjects With Mild to Moderate Alzheimer's Disease
Lead sponsor
T3D Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2015
Completion date
June 30, 2016
Enrollment
36 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease